Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CLBR 001 SWI 019 - Abbvie/California Institute for Biomedical Research

Next Previous
Drug Profile

CLBR 001 SWI 019 - Abbvie/California Institute for Biomedical Research

Alternative Names: CLBR-001+SWI-019; Switchable-CAR-T-cell-therapy - Abbvie/California Institute for Biomedical Research

Latest Information Update: 14 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie; California Institute for Biomedical Research
  • Class Antineoplastics; CAR-T cell therapies; Fab fragments; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I B-cell lymphoma

Most Recent Events

  • 14 Apr 2025 Calibr plans a phase I trial for Autoimmune disorders in May 2025 (NCT06913608)
  • 06 May 2024 Calibr completes a phase-I trial in B-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (Parenteral, Infusion) (NCT04450069)
  • 13 Apr 2023 Phase I clinical development in B-cell lymphoma (Combination therapy, Second-line therapy or greater) is ongoing in USA (IV) (Abbvie pipeline, April 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top